Sitafloxacin (INN; also called DU-6859a) is a fluoroquinolone antibiotic that shows promise in the treatment of Buruli ulcer.

3,4,5-Tricaffeoylquinic acid may attenuate the TNF-α±- and LPS-stimulated production of inflammatory mediators in keratinocytes by suppressing the Toll-like receptor 4 expression-mediated activation of the Akt, ERK and NF-κB pathways, it may exert an inhibitory effect against the pro-inflammatory mediator-induced skin disease.

Theralizumab (TGN1412) is an anti-CD28-targeting monoclonal antibody that directly stimulates T cells.